Top Page
Alterity Therapeutics
(OTC:ATH)
Alterity Therapeutics (ATH) vs. iShares MSCI Australia ETF (EWA)
Alterity Therapeutics Business Overview & Revenue Model
Alterity Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.44M | 5.44M | 4.02M | 3.92M | 5.12M | 4.34M |
| Gross Profit | 5.31M | 5.31M | 3.80M | 3.63M | 4.76M | 3.98M |
| EBITDA | -14.63M | -14.63M | -19.46M | -17.51M | -17.39M | -19.36M |
| Net Income | -12.15M | -12.15M | -19.12M | -13.81M | -12.85M | -15.31M |
Balance Sheet | ||||||
| Total Assets | 46.03M | 46.03M | 19.22M | 27.32M | 41.36M | 33.59M |
| Cash, Cash Equivalents and Short-Term Investments | 40.66M | 40.66M | 12.64M | 15.77M | 34.81M | 28.12M |
| Total Debt | 155.46K | 155.46K | 159.04K | 210.38K | 117.49K | 65.65K |
| Total Liabilities | 3.62M | 3.62M | 5.43M | 4.50M | 5.89M | 3.12M |
| Stockholders Equity | 42.40M | 42.40M | 13.80M | 22.81M | 35.47M | 30.47M |
Cash Flow | ||||||
| Free Cash Flow | -10.71M | -11.45M | -12.61M | -20.04M | -12.43M | -17.34M |
| Operating Cash Flow | -10.71M | -11.45M | -12.61M | -20.04M | -12.34M | -17.33M |
| Investing Cash Flow | -7.50M | -7.50M | -5.72K | -36.46K | -89.15K | -10.47K |
| Financing Cash Flow | 25.54M | 39.67M | 9.22M | 124.34K | 16.30M | 36.69M |
Alterity Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$105.20M | 15.29 | 27.24% | 2.67% | 0.65% | -9.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$160.50M | ― | ― | ― | ― | 0.66% | |
41 Neutral | AU$97.88M | ― | -42.68% | ― | ― | 63.46% | |
41 Neutral | $100.90M | ― | -83.09% | ― | ― | 55.94% | |
40 Underperform | $134.98M | ― | -81.03% | ― | -20.79% | 73.98% | |
40 Underperform | AU$106.68M | -13.09 | -47.98% | ― | 700.00% | 26.88% |
Alterity Therapeutics Corporate Events
Alterity Therapeutics Limited has announced the appointment of Julian Barbaczy as a director, effective November 21, 2025. The initial director’s interest notice indicates that Barbaczy does not hold any relevant interests in securities as a registered or non-registered holder, nor does he have any interests in contracts related to the company. This announcement is part of the company’s compliance with listing rules and corporate governance practices, ensuring transparency and accountability in its management structure.
Alterity Therapeutics Limited has announced the appointment of David Stamler as a director, effective November 21, 2025. This appointment is accompanied by a detailed disclosure of Stamler’s interests in the company’s securities, which include a significant number of fully paid ordinary shares and various options. This move is likely to impact the company’s governance and could influence its strategic direction, reflecting the company’s ongoing commitment to strengthening its leadership team.
Alterity Therapeutics Limited announced the cessation of Brian Meltzer as a director, effective November 21, 2025. This change in leadership involves Meltzer’s interests in a significant number of securities, including fully paid ordinary shares and various options, which may impact the company’s governance and strategic direction.
Alterity Therapeutics Limited has announced that Geoffrey Kempler has ceased to be a director as of November 21, 2025. The announcement details Kempler’s interests in securities, which include fully paid ordinary shares and unlisted options. This change in directorship may influence the company’s strategic direction and investor confidence, given Kempler’s significant holdings and involvement in the company.
Alterity Therapeutics announced the results of its 2025 Annual General Meeting, highlighting the approval of resolutions by shareholders. The company continues to make strides in its clinical trials, particularly with ATH434, which has shown positive results in treating Multiple System Atrophy, potentially enhancing its market position and impact on stakeholders.
Alterity Therapeutics has released a presentation by CEO Dr. David Stamler, emphasizing the company’s strategic direction and potential growth opportunities. The presentation highlights the company’s focus on advancing its objectives, though it acknowledges the inherent risks and uncertainties that could impact future outcomes.
Alterity Therapeutics announced significant progress at its 2025 Annual General Meeting, highlighting the completion of Phase 2 clinical trials for its lead asset, ATH434, in treating Multiple System Atrophy. The trials demonstrated a meaningful reduction in disease progression, earning FDA Fast Track and Orphan Drug Status, indicating strong commercial potential and hope for patients. The company is poised for late-stage clinical and commercial growth, with leadership transitions marking a new chapter in its journey.
Alterity Therapeutics has announced significant changes to its Board of Directors as it prepares for its next phase of growth, particularly advancing towards Phase 3 clinical development. Founding shareholder and former CEO Geoffrey Kempler is retiring, marking the end of a transformative era for the company. Brian Meltzer, a long-serving director, is also retiring. The company has appointed Dr. David Stamler as Managing Director and CEO, and Julian Barbaczy as Non-Executive Chair, both bringing extensive experience to support Alterity’s strategic vision and late-stage clinical development. These changes are aimed at ensuring continuity of governance and supporting the company’s drive towards meaningful outcomes for patients and shareholders.
Alterity Therapeutics Limited has disclosed a notice from Regal Funds Management Asia Pte Limited in compliance with the Australian Takeovers Panel Guidance Note 20 on Equity Derivatives. This disclosure involves long equity derivative positions related to Alterity’s securities, highlighting a significant stake held by the investment manager, which may impact the company’s market perception and investor relations.
Alterity Therapeutics announced that its CEO, David Stamler, will present a corporate update at the Bell Potter Healthcare Virtual Conference, highlighting the company’s advancements in neurodegenerative disease treatments. This presentation underscores Alterity’s commitment to addressing Parkinsonian disorders and its strategic positioning in the biotechnology sector, potentially impacting stakeholders by showcasing its clinical progress and future prospects.
Alterity Therapeutics presented promising data on ATH434 at the 36th International Symposium on the Autonomic Nervous System, highlighting its impact on orthostatic hypotension (OH) and disease progression in Multiple System Atrophy (MSA). The Phase 2 trial results showed that ATH434 stabilizes symptoms and enhances efficacy, particularly in the higher dose group, offering valuable insights for Phase 3 development. This progress underscores ATH434’s potential as a meaningful treatment option for MSA, with ongoing planning for Phase 3 trials and upcoming FDA interactions.
Alterity Therapeutics has reported promising results from its ATH434 trials, indicating a strengthened efficacy signal at high doses and a potential market opportunity of USD $2.4 billion in MSA treatment. The company is actively engaging with the FDA to advance ATH434 to Phase 3 trials, with a cash balance of A$54.56M as of September 2025, underscoring its commitment to developing a first-in-class therapy for MSA.
Alterity Therapeutics Limited has announced its Annual General Meeting scheduled for November 21, 2025, at Deloitte Australia’s offices in Melbourne. The company emphasizes the importance of shareholders submitting proxy forms and questions in advance to facilitate a well-prepared meeting. This announcement highlights Alterity’s commitment to transparent communication with its stakeholders and adherence to new provisions under the Corporations Act.
Alterity Therapeutics announced that data from its ATH434-201 Phase 2 clinical trial will be presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders. The trial results showed that ATH434 significantly improved clinical outcomes in MSA patients, demonstrating robust efficacy and safety, and has been granted Fast Track and Orphan Drug Designations by the FDA and European Commission. This development positions Alterity as a key player in the neurodegenerative disease treatment market, potentially offering the first-ever treatment for MSA.
Alterity Therapeutics has released a new commercial assessment for its lead drug candidate ATH434, aimed at treating Multiple System Atrophy (MSA), estimating potential global peak sales at USD $2.4 billion. The assessment, based on positive Phase 2 trial results, indicates strong interest from neurologists, with over 70% likely to prescribe ATH434 due to its efficacy in slowing disease progression and stabilizing symptoms, positioning Alterity favorably in the neurodegenerative treatment market.
Alterity Therapeutics has announced a change in the director’s interest notice, specifically regarding Brian Meltzer’s holdings. The notice reveals that there was a disposal of 7,000,000 unlisted options expiring on September 17, 2025, at $0.09, with no consideration involved. This change in holdings may impact the company’s stock dynamics and reflects ongoing adjustments in its governance and financial strategies.
Alterity Therapeutics Limited announced the cessation of 35 million securities due to the expiry of options without exercise or conversion as of September 17, 2025. This cessation may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategy and future growth prospects.
Alterity Therapeutics presented data from their Phase 2 clinical trial of ATH434 at the American Neurological Association Annual Meeting, showing the drug’s efficacy in slowing disease progression in Multiple System Atrophy (MSA) and its favorable safety profile. The trial demonstrated significant improvements in disease severity and motor performance, reinforcing ATH434’s potential as a disease-modifying therapy and generating optimism in the medical community.
Alterity Therapeutics has announced the issuance of over 1.6 billion fully paid ordinary shares, as per the regulations of the Corporations Act. This move is part of the company’s strategy to raise capital without the need for disclosure under Part 6D.2 of the Corporations Act, indicating compliance with necessary legal provisions and transparency requirements, which may impact its financial positioning and stakeholder confidence.
Alterity Therapeutics Limited announced the quotation of 1,666,666,663 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of September 15, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s financial flexibility and market presence, which could have implications for its strategic initiatives and stakeholder interests.
Alterity Therapeutics Limited announced a proposed issue of 1,666,666,663 ordinary fully paid securities, with the issue date set for September 15, 2025. This move is part of a placement or other type of issue, potentially impacting the company’s financial standing and market position by increasing its capital base, which may support ongoing research and development efforts.
Alterity Therapeutics has successfully raised A$20.0 million through a strategic placement of shares to international and Australian investors, strengthening its financial position. This funding will support the continued development of ATH434, a treatment for Multiple System Atrophy, and enhance the company’s clinical and regulatory strategies, positioning it for potential strategic partnerships.